Kornimate/medical-research-clean huggingface dataset:
hand therapy approach on lumbrical muscle tears in sport climbers

Conditions: Muscle Tear; Hand Injuries; Splints

Summary: this study aimes to analyze the effectiveness of a hand therapy protocol in the management of patients who suffer from a tear of a lumbrical muscle, regarding on the symptoms during the clinical examination, the disability in their activities of daily living and the sports-specific function.

a prospective intervention study is performed on 50 adult climbers suffering from an injury of the 4th lumbrical muscle. they wear during 3 weeks a 5th finger extension relative motion orthosis, while pain-free sport activities are permitted using a 4th and 5th fingers buddy-taping. after three weeks, patients are told to progressively remove the splint and, after six weeks, the splint is totally removed. symptoms in the lumbrical stress test are evaluated during the 6 weeks period using dynamometry and goniometry, finally, quick-disabilities of the arm shoulder and hand questionnaire is also analyzed.

Eligibility criteria:
inclusion criteria: * adult climbers suffering from an injury of the 4th lumbrical muscle exclusion criteria: * patients with previous treatments. * patients with concomitant injuries or illness

Keywords: lumbrical sport climbing hand therapy hand injuries relative motion
short-term health effects of wild blueberry juice consumption

Conditions: Pre-diabetes

Summary: researchers at the university of prince edward island want to learn about the health effects of wild blueberry juice.


Eligibility criteria:
inclusion criteria: * healthy individuals at risk for type 2 diabetes exclusion criteria: * have a body mass index of less than 20 and greater than 45 kg/m2. * are less than 21 and greater than 65 years old at beginning of study * have smoked or used tobacco within 6 months prior to the start of the study * are pregnant, plan to become pregnant or become pregnant during the study * have a history or presence of kidney disease, liver disease, certain cancers, gastrointestinal, other metabolic diseases, or malabsorption syndromes * have type 2 diabetes and need to use oral diabetic drugs or insulin * have an allergy or adverse reaction to blueberries
the effects of exenatide after gastric restriction

Conditions: Morbid Obesity

Summary: the purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (lagb) with twice daily exenatide or placebo injections.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years, 2. have a body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities (1991 nih guidelines for bariatric surgery), 3. for women of childbearing age, must have a negative pregnancy test at screening, and agree to use barrier contraceptives for the duration of the study, and 4. are able to understand and comply with the study process, and give informed consent. exclusion criteria: 1. a diagnosis of type 1 diabetes mellitus, 2. a diagnosis of type 2 diabetes mellitus (a diagnosis of t2dm will be a previous fasting plasma glucose greater than or equal to 126 mg/dl, or a random plasma glucose greater than 200 mg/dl), 3. have experienced hypersensitivity reaction or a worsening of glycemic control on byetta® (exenatide), 4. patients with end stage renal disease or severe renal impairment, 5. patients with severe gastrointestinal disease, including gastroparesis, 6. liver function tests 2.5 standard deviations above normal values, 7. contraindication for bariatric surgery, 8. treatment with exenatide (byetta) in the last three months, 9. currently using or have used within three months before this trial: sibutramine, orlistat, or phentermine(patients must also agree to not use these medications for the duration of the study), 10. treatment with any investigational drug in the last 30 days, 11. active malignancy, liver of kidney failure, symptomatic coronary heart disease, or severe psychiatric disease, 12. history of malignancy other than basal cell skin carcinoma, or 13. in the opinion of the investigator, patient is abusing alcohol and/or drugs.

Keywords: morbid obesity lap band adjustable gastric band exenatide byetta weight loss bariatric surgery
metabolic control adolescents type 1 diabetes

Conditions: 13-18 Year; Diagnosed at Least 6 Months Ago; HbA1C> 7.5; Being Able to Read and Write

Summary: purpose of the research; the aim of this study is to examine the effect of education including peer-interactive group support to be given to adolescents diagnosed with type 1 diabetes with poor glycemic control in the 13-18 age group on metabolic control of adolescents.

the lack of a certificate program specific to pediatric diabetes nursing of the ministry of health in our country and the insufficient number of diabetes education nurses show that the pediatric population is not adequately trained to provide diabetes management. along with these obstacles, the lack of use of an evidence-based standard education program reveals the need for effective intervention programs that include approaches specific to adolescents, who are a particularly risky group. peer interaction can be used as an effective approach to increase adolescents' adherence to treatment. thus, adolescents who isolate themselves are given the opportunity to cope with the disease and to share with other children. it has been determined that there is no study in the literature that includes peer-interactive group support on adolescents with a diagnosis of type 1 diabetes who have poor glycemic control but have repeated hospitalizations. this situation shows that there is a need for a study to evaluate the effect of educational intervention including peer-interactive group support on repeated hospitalizations in adolescents with type 1 diabetes.

Eligibility criteria:
inclusion criteria: * be between 13-18 years old * diagnosed at least 6 months ago * hba1c level \> 7.5 * having repeated hospitalizations at least twice * living in mersin city center * being able to communicate in turkish * being able to read and write exclusion criteria: * - using an insulin pump * having a chronic disease other than diabetes, * diseases that affect cognitive functions, hearing and vision impairments

Keywords: type 1 diabetes metabolic control adolescence nursing
reducing opioid prescription after kidney stone removal surgery

Conditions: Kidney Stone

Summary: the purpose of this study is to implement and assess a standard way of prescribing opioid pain medication following pcnl (a kidney stone removal surgery) to ensure patients are being discharged with an appropriate quantity of pain management medication.

participants in this study will have their opioid pain medication prescription at discharge following pcnl (percutaneous nephrolithotomy, a kidney stone removal surgery) determined by an algorithm in addition to physician judgement. the goal of the algorithm is help physicians refine pain medication prescribing patterns for patients who have undergone pcnl in order to discharge patients with an appropriate quantity of pain management medication. the effectiveness of the algorithm will be assessed through participant surveys. participants will complete a brief online survey on days 3, 7, and 14 following hospital discharge and another phone-based survey 26-30 days after hospital discharge.

Eligibility criteria:
inclusion criteria: - patients undergoing percutaneous nephrolithotomy at mayo clinic rochester. exclusion criteria: * unable or unwilling to provide informed consent. * patients who require intensive care unit admission after surgery. * patients who have clavien grade iii or greater postoperative complications requiring additional intervention \< 30 days after index procedure.

Keywords: percutaneous nephrolithotomy (pcnl)
resiliency in older adults undergoing bone marrow transplant

Conditions: Leukemia; Lymphoma; Blood Cancer; Myelodysplastic Syndrome; Acute Myelogenous Leukemia; Non-Hodgkins Lymphoma

Summary: the objective of this research is to measure certain indicators of resiliency to better understand which participants who are over 60 years old will respond more positively to bone marrow transplant. this research is being done to determine if there are traits that make recipients more likely to bounce back following allogeneic bone marrow transplant (bmt).

allogeneic blood and marrow transplantation (allobmt) is the only potentially curative therapy for many forms of leukemia, lymphoma, and other hematologic malignancies. as with many forms of cancer, many of the most common indications for allobmt disproportionally affect older people. although treatments have improved for older adults undergoing therapies for these diseases, the outcomes are variable and there is little biological knowledge to help identify specific factors that would predict why some people do well with treatment and others develop functional and cognitive decline and other adverse health outcomes. data specific to patients older than 60 who have undergone allobmt are sparse even though the 1 year non-relapse mortality rate in patients older than age 50 at johns hopkins is 12%. in none of these studies have geriatric assessment measures in domains such as cognition and function been evaluated. given the low incidence of non-relapse mortality in the investigators' older patients, the investigators have a unique opportunity to study the factors that influence not only mortality but function after hematopoietic stem cell transplantation. the investigators aim to be able to counsel patients more specifically about likely outcomes after transplant.

Eligibility criteria:
inclusion criteria: * undergoing allogeneic bone marrow transplant at johns hopkins hospital, the indication for which is a hematologic malignancy * age ≥60 years * ability to walk without human assistance * enrollment in concomitant clinical research is permitted but not required * english-speaking * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * unwillingness or inability to return at 6 months after transplantation for repeated evaluation * non-english-speaking

Keywords: allogeneic blood and marrow transplantation (allobmt) resiliency rebound over age 60
repeat dose gw685698x with magnesium stearate, excipient bridging study, in healthy volunteers

Conditions: Asthma

Summary: gw685698x is a novel glucocorticoid receptor agonist that is being developed as an orally inhaled treatment for asthma. in previous studies inhaled gw685698x was administered as a dry powder containing either lactose alone or lactose and cellobiose octaacetate. however, future dry powder gw685698x formulations will contain lactose and magnesium stearate. this study will be the first administration of this new gw685698x dry powder formulation in man and will provide safety and tolerability data to support the further development of this formulation.


Eligibility criteria:
inclusion criteria: * healthy volunteers, * aged 18-65 * male and females (females of non-child bearing potential or who meet the contraception criteria). * bmi - 19-31 kg/m2 exclusion criteria: * history of breathing problems

Keywords: healthy volunteers
assessing the magnitude of anisometropia in patients wearing misight 1 day contact lens

Conditions: Myopia; Anisometropia

Summary: the effectiveness of misight 1 day contact lens in retarding anisometropic progression has not been investigated before. this study is aimed to elucidate the efficacy of misight 1 day contact lens for anisometropia control.


Eligibility criteria:
inclusion criteria: * 8-23 years old children diagnosed with anisometropia and are willing to accept misight® 1 day contact lens wearing treatment. * no congenital eye diseases or eye diseases such as strabismus and amblyopia. * those who have been stated to be willing to participate in the program for at least 24 months and accept various evaluations. exclusion criteria: * ocular surface disease( dry eye, keratoconus..) * allergy to contact lens * received eye surgery before * the cornea is infected (bacterial, fungal or viral infection). * strabismus * premature birth
anaysis of phytotherapy agent against periodontitis

Conditions: Periodontitis

Summary: in light of the controversy that are already approved but that however still exists regarding the efficacy and influence of the decontaminant tools for the management of periodontitis (, the aim of this study was to evaluate, at 6 months follow-up, the post-treatment clinical parameters and immunological and gingival microbial profiles in patients with periodontitis, treated by either srp in addition to phytotherapeutic drug or srp alone.

this trial was conducted in accordance with the world medical association's declaration of helsinki of 1975, and reviewed in 2008. the local ethical committee of the university of messina approved the study protocol and each patient was carefully informed about the possible inherent risks of the study and provided their informed written consent 34 patients, 18 men and 16 women, aged 27 to 65 (mean age 44.2) were assessed for eligibility . in all subjects, subgingival plaque was acquired from 4 separate proximal sites at 365 days after therapy. the gingival crevicular fluid (gcf) was gathered, at the same time from other four different non-contiguous interproximal sites using filter paper strips‡ as previously described. the levels of il-1β, il-10 and tnf-α were recognized by conventional enzyme-linked immunosorbent assay using an equation with software using a five polynomial parameter. each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, were treated as conventional scaling and root planing (srp) + phytotherapeutic drug (neuridase), while the other group were treated as conventional srp alone

Eligibility criteria:
inclusion criteria: 1. good condition of general health, 2. a minimum of 2 teeth for each quadrant with a pocket depth (pd) ranging from 4-6 mm, 3. no involvement of the furcation, 4. a minimum of a six teeth per quadrant, respectively. exclusion criteria: 1. periodontal therapy during the last 12 months, 2. assumption of antibiotics during the last 6 months, 3. pregnancy, 4. any systemic condition which might affect the effects of the study treatment, 5. previous or current radiation or immunosuppressive therapies, 6. use of mouthwash containing antimicrobials during the previous 3 months, 7. no use of hormonal contraceptives, 8. medication by anti-inflammatory and immunosuppressive drugs, 9. previous history of hard-drinking, 10. smoking, 11. class ii and iii tooth mobility.
long term study of avonex therapy following a first attack of multiple sclerosis

Conditions: Multiple Sclerosis; Optic Neuritis; Transverse Myelitis; Acute Brainstem/Cerebellar Syndrome

Summary: the current study is a continuation of the 5 year extension study of the phase iii champs study (see reference). this study was designed to determine if immediate initiation of therapy with interferon beta-1a (avonex) after a first attack of multiple sclerosis (ms) continues to delay the development of further attacks (cdms) and the development of neurological disability over a 10 year period of observation. the initial 5 year extension study, called champions5, reported that immediate initiation of interferon beta-1a (avonex) after a first attack of ms continued to delay the development of cdms and lowered relapse rates compared to delayed initiation of disease modifying treatment (usually with avonex) either at the time of a second attack or at the end of the phase iii study (24 months). the study was extended to 10 years to determine if these effects are sustained and result in less long term permanent disability.

the champs study determined that immediate initiation of interferon beta 1a therapy (avonex) immediately following a first clinical demyelinating event in high risk patients (i.e. those with at least 2 asymptomatic white matter lesions on cranial mr imaging \> 3 mm in diameter or ovoid) delayed the development of clinical definite multiple sclerosis (cdms)(as defined by a second, clinically verifiable attack involving another part of the central nervous system) over 2 years of observation and significantly decreased the development of new or enlarging white matter lesions on mri over 18 months (see reference). the current study is a long term extension of a cohort of champs study site and participants. the three main aims of the study are as follows: 1. to determine the long term neurological outcome in patients treated with interferon beta 1a (avonex) from onset of a first clinical demyelinating event 2. to determine if immediate initiation of avonex therapy (the champs avonex treatment group) confers long term benefits compared to delayed initiation of therapy (the champs placebo group) on the rate of development of cdms, annualized relapse rates, the development of permanent disability and mr measures of disease activity and progression. 3. to determine predictors of long term disease activity and disability in patients following a first clinical demyelinating event

Eligibility criteria:
inclusion criteria: * previous participation in champs study * participation in a study site willing to participate in the champions10 extension study * willingness to enroll in the champions 10 extension * willingness to sign informed consent exclusion criteria: * discovery of an alternative neurological disorder other than ms as a cause of initial neurological symptoms * a severe systemic disease with likely mortality within 3 years

Keywords: multiple sclerosis interferon beta mri optic neuritis transverse myelitis
comparing two group therapy treatments for binge eating disorder

Conditions: Eating Disorders

Summary: this study will compare two different approaches for the treatment for binge eating disorder.

binge eating disorder (bed) is associated with impairments in physical, psychological, and social functioning. research has revealed relationships between disordered eating and both low self-esteem and negative emotional states. participants in this study will complete assessment interviews regarding their eating disorder and associated problems. similar assessments will be conducted at the end of the study. participants will then be randomly assigned to one of two therapy groups. participants in one group will focus on the role of self-esteem, self-awareness, and personal effectiveness in binge eating. participants in the other group will focus on the role of negative emotions and binge eating. both treatments will involve a 30 to 40 minute pre-treatment individual orientation session, followed by 20 weeks of weekly group therapy. sessions will take place over 22 weeks, or approximately 6 months (18 weekly sessions followed by 2 biweekly sessions). follow-up assessments will take place at 3 months, 6 months, and 12 months after study completion to assess maintenance of treatment effects.

Eligibility criteria:
inclusion criteria: * diagnosis of binge eating disorder * reside in the san francisco bay area * willing to commit to the study requirements exclusion criteria: * unstable medical problems * history of bipolar illness or schizophrenia * receiving treatment for an eating disorder (or unwillingness to discontinue treatment upon study entry) * membership in weight-loss groups such as weight watchers or jenny craig (or unwillingness to discontinue membership upon study entry) * use of medications affecting weight or appetite. antidepressants are acceptable, but doses of any psychiatric medication must have been stable for at least 3 months prior to study start * breast-feeding * require gastric-bypass surgery

Keywords: psychotherapy treatment
building empowerment and coping outcomes for cancer patients, survivors and their caregivers

Conditions: Cancer; Caregiving Stress; Caregiver Burnout; Survivorship

Summary: cancer has a psychological, emotional and social impact beyond a patient's physical health. this study examines three new online peer mental-wellness support program for cancer patients, survivors or their caregivers. each program teaches evidence-based skills, in the context of that groups lived experience, to manage the emotional impact of cancer. this study examines the impact of that program.

cancer has a psychological, emotional and social impact beyond a patient's physical health. these problems often ripple beyond the individual with the diagnosis, to their broader community, and also beyond a cancer treatment course into survivorship. as a result, there are a wide range of socioemotional needs in those who have been impacted by cancer. further, these emotional impacts have a direct impact on morbidity and mortality of cancer. a new peer mental-wellness support program, called color cancer connect (ccc) supports cancer patients, survivors and their caregivers by teaching them evidence-based skills to manage the emotional impact of cancer. this study will examine all three programs (i.e., patient, survivor, caregiver) to gather data to measure the impact of the program on emotional well-being, quality of life and health behaviors.

Eligibility criteria:
inclusion criteria: * lived experience as either a current cancer patient, cancer survivor or caregiver of someone with cancer * adult - 18+ * has health insurance provided by employer or union (can be dependent of person on insurance) * read/speak english * have access to internet and personal email account exclusion criteria: * severe mental illness that is disruptive to other group members

Keywords: cancer caregiving emotional support psychology
evaluation of the position of promontofixation prostheses in perineal ultrasound

Conditions: Prolapse of the Uterus

Summary: indirect promontofixation with prostheses is the standard surgical technique for the reference of uterine prolapse. there is no validated examination to control the position of the prostheses postoperatively. these prostheses are echogenic and perineal ultrasound could be a means of postoperative monitoring. there is no data in the literature on the relationship between prosthesis position and postoperative symptoms


Eligibility criteria:
inclusion criteria: * age ≥ 18 years of female sex * patient with double laparoscopic promontofixation without associated hysterectomy exclusion criteria: * history of hysterectomy * anterior cure (before index intervention) of prolapse with placement of prosthetic material.